Publications
187
Citations
10,531
Est. group size
~18
Recurring co-author estimate
Active years
21
Publishing since 2005
Matthew C. Exline studies critically ill patients in intensive care, with a strong focus on respiratory infections such as COVID-19, influenza, and respiratory syncytial virus (RSV). His work often involves large multi-hospital studies measuring vaccine effectiveness, disease severity, and clinical trial testing of treatments for sepsis and related complications. This research is aimed at improving hospital care and public health decisions for patients with severe respiratory illness and sepsis.
Publication output grew substantially from 2017 to a peak around 2022, dipped in 2023, and rebounded to high levels in 2024 and 2025, suggesting an active and expanding research program in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Genomic Characterization of RSV in the US by Vaccination Status
JAMA · 2025
- COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019–2022
Vaccine · 2025
- Patient- and Community-Level Characteristics Associated With Respiratory Syncytial Virus Vaccination
JAMA Network Open · 2025
- Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024
The Journal of Infectious Diseases · 2025
- Comparison of immunization information systems, electronic medical records, and self-report to ascertain RSV vaccination status among US adults aged ≥60 years, 2023–2024
Vaccine · 2025
- Effectiveness of 2024–2025 COVID-19 Vaccination Against COVID-19 Hospitalization and Severe In-Hospital Outcomes — IVY Network, 26 Hospitals, September 1, 2024–April 30, 2025
medRxiv · 2025
- Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Sepsis-associated Acute Respiratory Failure: A Phase 3 Randomized Placebo-controlled Trial
American Journal of Respiratory and Critical Care Medicine · 2025
- Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Sepsis-Associated Acute Respiratory Failure: A Phase 3 Randomized Placebo-Controlled Trial
American Journal of Respiratory and Critical Care Medicine · 2025
- Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults with Respiratory Syncytial Virus
medRxiv · 2025
- Association of Oxygen Mask Type With Incidence of Hypoxia During Emergency Tracheal Intubation: A Secondary Analysis of Two Multicenter Clinical Trials
American Journal of Respiratory and Critical Care Medicine · 2025
- Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
Clinical Infectious Diseases · 2025
- Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
MMWR Morbidity and Mortality Weekly Report · 2024
- Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
JAMA Network Open · 2024
- Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL)
Intensive Care Medicine · 2024
- Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
Clinical Infectious Diseases · 2024
- MMWR Morbidity and Mortality Weekly Report×18
- Clinical Infectious Diseases×12
- medRxiv×9
- Critical Care Medicine×7
- JAMA×6
- Rachel Martin‐Blais
Medicine · The Ohio State University
- Zachary Smith
Medicine · The Ohio State University
- Sarah Karow
Medicine · The Ohio State University
- Jaffar A. Al‐Tawfiq
Medicine · Indiana University
- Jingyou Yu
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile